Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands
Saudi Pharmaceutical Journal · 2024-01 · 32 (1) · 101915
DOI: 10.1016/j.jsps.2023.101915 ↗Kurz gefasst
Fachartikel in der Zeitschrift Saudi Pharmaceutical Journal, 2024-01. Verfasst von Shazia Hussain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Higher Education Commision, Pakistan, Higher Education Commission Pakistan.
Abstract (Originalsprache)
In this study we presented a novel series of NNO tridentate ligands generating imino, amido and oxo donor pocket for Pd(II) coordination. All the compounds were meticulously characterized by elemental analysis and advanced spectroscopic techniques, including FTIR, proton and carbon NMR. The synthesized compounds underwent rigorous evaluation for their potential as anti-cancer agents, utilizing the aggressive breast cancer cell lines MDA-MB (ATCC) and MCF-7 as a crucial model for assessing growth inhibition in cancer cells. Remarkably, the MTT assay unveiled the robust anti-cancer activity for all palladium complexes against MDA-MB-231 and MCF-7 cells. Particularly, complex [Pd(L1)(CH3CN)] exhibited exceptional potency with an IC50 value of 25.50 ± 0.30 µM (MDA-MB-231) and 20.76 ± 0.30 µM (MCF-7), compared to respective 27.00 ± 0.80 µM and 24.10 ± 0.80 µM for cisplatin, underscoring its promising therapeutic potential. Furthermore, to elucidate the mechanistic basis for the anti-cancer effects, molecular docking studies on tyrosine kinases, an integral target in cancer research, were carried out. The outcome of these investigations further substantiated the remarkable anticancer properties inherent to these innovative compounds. This research offers a compelling perspective on the development of potent anti-cancer agents rooted in the synergy between ligands and Pd(II) complexes and presenting a promising avenue for future cancer therapy endeavors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
- Center of Regenerative Medicine and Stem Cell Research, Aga Khan 74800, University Karachi, Pakistan.
- Natural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Sultanate of Oman and Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Khyber Pakhtunkhwa, Pakistan.
- Department of Chemistry, University of Gujrat, Gujrat 50700, Pakistan.
- Department of Physics, University of Sargodha, 40100 Sargodha, Pakistan.
Förderung
- Higher Education Commision, Pakistan
- Higher Education Commission Pakistan
Zitieren
APA
Hussain, S., Hussain, S., Zafar, M. N., Hussain, I., Khan, F., Mughal, E. U., & Tahir, M. N. (2024). Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands. Saudi Pharmaceutical Journal, 32(1), 101915. https://doi.org/10.1016/j.jsps.2023.101915
Vancouver
Hussain S, Hussain S, Zafar MN, Hussain I, Khan F, Mughal EU, et al. Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands. Saudi Pharmaceutical Journal. 2024;32(1):101915. doi:10.1016/j.jsps.2023.101915
BibTeX
@article{Hussain2024,
author = {Hussain, Shazia and Hussain, Shabeeb and Zafar, M Naveed and Hussain, Irfan and Khan, Faizullah and Mughal, Ehsan Ullah and Tahir, Muhammad Nawaz},
title = {Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands},
journal = {Saudi Pharmaceutical Journal},
year = {2024},
volume = {32},
number = {1},
pages = {101915},
doi = {10.1016/j.jsps.2023.101915}
}
EUVIMED